45 clinical trials found.
-
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
This study is investigating a drug called AMG 305, which is designed to target specific cancer cells that have CDH3 and MSLN. This is a ...
Phase
TRIAL ROLE: Sub Investigator
-
A Master Protocol for the Multi-Cohort Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
This study is testing a medicine called DCC-3116 along with other cancer treatments for patients with advanced malignancies. The study team split the study into ...
Phase
TRIAL ROLE: Sub Investigator
-
KontRASt-03: A Phase Ib/II multicenter open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation
This study will focus on two types of cancer: non-small cell lung cancer and colorectal cancer. The purpose of the study is to find out ...
Phase
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL STUDY OF GV20-0251 IN PATIENTS WITH ADVANCED AND/OR REFRACTORY SOLID TUMOR MALIGNANCIES
This study has two parts, Part A and Part B, and will be testing the drug GV20-0251 to see how well it can help patients ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
This study is designed for patients diagnosed with advanced NSCLC and other solid tumors with an ALK mutation. (NYU-Nuvalent NVL-655)
Phase
TRIAL ROLE: Sub Investigator
-
A first-in-human Phase I non-randomized open-label multicentre dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6
This study is testing different doses of a dtreatment called BI 765049, either alone or with another drug called ezabenlimab for patients with tumors expressing ...
Phase
TRIAL ROLE: Sub Investigator
-
An Open-Label Multicenter Phase 1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to assess the Safety, Tolerability ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2a Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
The purpose of the study is to look at safety and tolerability of orally administered CLN-081 monotherapy, as single dose and after multiple doses over ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
We want to know the safety and tolerability of the anti-programmed death 1 (PD-1) antibody nivolumab at different dose levels for patients with autoimmune disorders ...Phase
TRIAL ROLE: Sub Investigator
-
Site for Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
The purpose of the study is to determine whether docetaxel alone is as active as docetaxel and cetuximab combination and whether either taxane-based regimen is ...Phase
TRIAL ROLE: Sub Investigator
